Navigation Links
Nephros Reports 2011 Fourth Quarter and Full Year Financial Results
Date:3/22/2012

issued a Request For Proposal (RFP), and Nephros has no information regarding when or if an RFP applicable to the UF-40 ultrafilter may be put forth by the U.S. Army.

Nephros is evaluating a range of additional commercial, industrial, and military opportunities for its ultrafiltration technology.

The executive search being conducted by DHR International for a permanent CEO for Nephros is actively ongoing.  Nephros anticipates to completion of the search within the first half of 2012.

About Nephros, Inc.

Nephros, Inc., headquartered in River Edge, New Jersey, is a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification.

The Nephros hemodiafiltration (HDF) system is designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient while addressing the critical financial and clinical needs of the care provider. ESRD is a disease state characterized by the irreversible loss of kidney function. The Nephros HDF system removes a range of harmful substances more effectively, and with greater capacity, than existing ESRD treatment methods, particularly with respect to substances known collectively as "middle molecules." These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient.

The Nephros Dual Stage Ultrafilter (DSU) is the basis for the Nephros line of water filtration products, which includes the MSU and SSU ultrafilters. The patented dual stage cold sterilization ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses, parasites and biotoxins. The Nephros DSU, MSU, and SSU are FDA cleared for the filtration of biological contaminants from water and bicarbonate concentrate used in hemodialysis procedures. 
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
2. Nephros Reports 2009 Third Quarter Financial Results
3. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
4. Nephros Signs Development Agreement with STERIS
5. Nephros Reports 2010 First Quarter Financial Results
6. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
7. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
8. Nephros Reports 2010 Second Quarter Financial Results
9. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
10. Nephros Reports 2010 Third Quarter Financial Results
11. Nephros Rights Offering Registration Statement Declared Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2014. Cash ... $301.4 million as compared to $309.1 million at March 31, ... for Nektar as we look forward to significant milestones for ... Robin, President and Chief Executive Officer of Nektar. "The first ...
(Date:7/31/2014)... Mass. , July 31, 2014 /PRNewswire/ ... funding changes brought about by the Affordable ... reimbursement and prescribing of pharmaceutical therapies. The ... cover beneficiaries through new regulations and expanded ... occurring in the health exchanges—state-based marketplaces set ...
(Date:7/31/2014)... Portugal , July 31, 2014 ... Cork, Ireland has successfully passed a pre-approval inspection ... The inspection, carried out by the FDA Consumer Safety Officer, ... planned, started on 21 st July and concluded on ... be compliant with the principles and guidelines of Good Manufacturing ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2
... Feb. 15, 2011 Baxano, Inc. ( w w ... om ) today announced the addition of George A. Harter, ... Officer, Mr. Harter will be responsible for Finance, Administration and Human ... for Acclarent, Inc. from 2005 to 2011, through its acquisition by ...
... 2011 Takeda Pharmaceuticals International, Inc., a wholly-owned ... that its Pharmaceutical Development Division has entered into ... ) and Quintiles, two of the world,s largest ... of the agreements, Covance and Quintiles will work ...
Cached Medicine Technology:Baxano, Inc. Names George A. Harter, Jr. as Chief Financial Officer 2Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles 2
(Date:7/31/2014)... To further educate the public, The Rothenberg ... safety information regarding leaving children in hot vehicles: , ... consequences. Because a child’s body can heat up three ... children alone in a hot vehicle puts them at ... Statistics of Children Left Alone in a Car , ...
(Date:7/31/2014)... Most mommy blogs are simple family ... is to attract all mothers from all walks of ... group; whether its high fashion or child rearing. When ... on the Internet was so segmented. “I found myself ... topic and then search Google to get information on ...
(Date:7/31/2014)... A chance meeting at last April’s ... country artist/writer-producer Jimmy Robbins to Etymotic Research and ... an innovator in hearing wellness solutions, and maker ... 2012, Etymotic’s Music•PRO® Electronic Earplugs have revolutionized hearing ... and restoring natural hearing when hearing is not ...
(Date:7/31/2014)... 31, 2014 (HealthDay News) -- Transplant surgeons often ... flags for burnout, a new study suggests. ... study reported having a low sense of personal ... feeling emotionally exhausted, researchers found. "Burnout is ... transplantation," study co-author Dr. Marwan Abouljoud, director of ...
(Date:7/31/2014)... July 31, 2014 Joseph M. Lee, ... Hudson Valley (CDHV), a leading provider of quality cardiovascular ... Hudson Valley. Dr. Lee is a board certified ... , In addition to his position at CDHV, ... New York-Presbyterian Hospital/ Columbia University Medical Center. Dr. Lee ...
Breaking Medicine News(10 mins):Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 2Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 3Health News:Mommylish Launches Its Website 2Health News:Country Star Jimmy Robbins Now Using Etymotic’s MusicPRO Electronic Earplugs 2Health News:Burnout Common Among Transplant Surgeons, Study Reveals 2Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 2Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 3
... nutritional supplements ... in North ... Alliance,(CWA), experts in designing custom wellness programs for consumers and,corporations, ... announcement was made by biochemist, Lyle MacWilliam, author,of the recently ...
... many,people who have called and asked how they could help, ... with Tony Snow,s children,s education and,expenses., Jill Snow, Tony,s ... Kendall, Robbie and Kristi, as beneficiaries. Donations can,be made directly ... check,made payable to the "Tony Snow Family Trust" to:, ...
... ANGELES, July 14 The Cooperative of American,Physicians, ... exceeded 10,000 physicians., "Surpassing the 10,000 member ... CEO James L. Weidner. "The physicians who founded,CAP ... They believed that,physicians working together could find a ...
... with upbeat outlook, but same did not hold true for women ... had a lower risk of dying from heart disease turned out ... their conventional risk factors showed. , The death rate for men ... of those who listed themselves as being at average risk, said ...
... The Medical Device,Manufacturers Association (MDMA), a national trade ... the Board of Directors at the,MDMA Annual Meeting ... http://www.newscom.com/cgi-bin/prnh/20041004/MDMALOGO ), "I am honored to ... Manufacturers,Association," stated Root. "MDMA has a long history ...
... in heart and travels to the brain, heparin more risky, ... widely prescribed blood-thinning drug heparin is associated with an increased ... cardioembolic stroke, new research shows. , But another thinning ... in the same group of patients. , This finding led ...
Cached Medicine News:Health News:Vitalize(TM) Receives Top Multivitamin Rating 2Health News:Cooperative of American Physicians Membership Tops 10,000 2Health News:Optimism About Heart Risk Pays Off 2Health News:Vascular Solutions CEO Elected to MDMA Board of Directors 2Health News:Warfarin Safer Than Heparin for Some Strokes 2
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 45 degrees....
Titanium. 0.12 mm 1 x 2 teeth with 6 mm platform and 2.0 mm angled tips. Flat serrated handle, dull finish....
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
Narrow 4 mm long smooth platform. Serrated handle with polished finish....
Medicine Products: